- Q1 2024 Vivoryon Therapeutics NV Earnings Call TranscriptMay 23, 2024€8.13Earnings
- Q4 2023 Vivoryon Therapeutics NV Earnings Call TranscriptApr 24, 2024€8.13Earnings
- Q3 2023 Vivoryon Therapeutics NV Earnings Call TranscriptDec 06, 2023€8.13Earnings
- Vivoryon Therapeutics NV at Virtual R&D Event with Key Opinion Leaders TranscriptOct 17, 2023
- Half Year 2023 Vivoryon Therapeutics NV Earnings Call TranscriptSep 07, 2023€8.13Earnings
- Q4 2022 Vivoryon Therapeutics NV Earnings Call TranscriptApr 19, 2023€8.13Earnings
- Vivoryon Therapeutics NV at Barclays Global Healthcare Conference TranscriptMar 16, 2023
- Q3 2022 Vivoryon Therapeutics NV Earnings Call TranscriptNov 22, 2022€8.13Earnings
- Q2 2022 Vivoryon Therapeutics NV Earnings Call TranscriptSep 30, 2022€8.13Earnings
- Vivoryon Therapeutics NV Corporate Call TranscriptAug 02, 2022
- Vivoryon Therapeutics NV Annual Shareholders Meeting TranscriptJun 22, 2022
- Q4 2021 Vivoryon Therapeutics NV Earnings Call TranscriptApr 28, 2022€8.13Earnings
- Q2 2021 Vivoryon Therapeutics NV Earnings Call TranscriptSep 21, 2021€8.13Earnings
Q4 2022 Vivoryon Therapeutics NV Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the Full Year 2022 Results Earnings Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, [Anne Doering]. Please go ahead.
Thank you, Heidi. Good afternoon, and thank you for joining us today for Vivoryon's conference call to discuss the company's full year 2022 results and operational progress. This morning, Vivoryon issued a press release reporting its full year 2022 results, which is posted on the company's website at www.vivoryon.com.
On the call with me today are Uli Dauer, Chief Executive Officer of Vivoryon; and Florian Schmid, our Chief Financial Officer. Also with us on today's call and available for questions is Michael Schaeffer, our Chief Business Officer. We will begin today's call with opening remarks from Uli on Vivoryon's clinical and operational progress and then Florian will review the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)